Scotland-headquartered pharmaceutical firm Prostrakan has drawn down £5 million from an agreed £50 million loan facility to snap up distressed assets
Related Topics
Early Stage Funding
Scotland-headquartered pharmaceutical firm Prostrakan has drawn down £5 million from an agreed £50 million loan facility to snap up distressed assets